NSRX Nasus Pharma, Ltd.
Price Chart
Executive Summary
Nasus Pharma announced positive Phase 2 results for its intranasal epinephrine candidate NS002, showing significantly faster epinephrine absorption compared to EpiPen®. The drug achieved a median time to therapeutic threshold of 1.69 minutes versus 3.42 minutes for EpiPen®, with strong performance across multiple dosing scenarios and no serious adverse events. The company plans to initiate a pivotal study in Q4 2026.
Actionable Insight
Traders should monitor upcoming regulatory interactions and pivotal trial initiation in Q4 2026. Given the strong Phase 2 data and needle-free advantage, any positive developments could drive significant upside in this small-cap biotech. Consider positioning ahead of pivotal study launch.
Key Facts
- NS002 achieved median T100 (time to 100 pg/mL epinephrine) of 1.69 minutes vs. 3.42 minutes for EpiPen® (p=0.033)
- At 5 minutes, 88.4% of NS002 patients reached therapeutic threshold vs. 64.6% for EpiPen®
- NS002 showed ~50% higher epinephrine exposure in the first 10 minutes compared to EpiPen®
- No serious adverse events reported; favorable safety profile confirmed
- Pivotal study planned for Q4 2026
Financial Impact
No direct financial figures disclosed, but successful pivotal trial could position NS002 as a major competitor in the multi-billion dollar anaphylaxis treatment market
Risk Factors
- Phase 2 success does not guarantee pivotal trial outcomes
- Regulatory hurdles for approval of a new epinephrine delivery method may be high
- Competition from established autoinjectors and potential generic entrants
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3256155 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 1, 2026
10w ago
|
EFFECT
| $2.55 $2.56 | ▼ −0.39% | ▲ +9.33% | $2.88 (−12.94%) |
|
Mar 28, 2026
11w ago
|
3
| $2.01 $2.91 | ▲ +44.78% | ▲ +32.18% | $2.88 (+43.28%) |
|
Mar 28, 2026
11w ago
|
3
| $2.01 $2.91 | ▲ +44.78% | ▲ +32.18% | $2.88 (+43.28%) |
|
Mar 25, 2026
11w ago
|
Press Release
| $2.76 $3.40 | ▲ +23.19% | ▲ +15.33% | $2.88 (+4.35%) |
|
Mar 16, 2026
12w ago
|
Press Release
| $3.10 $2.25 | ▼ −27.42% | ▼ −31.20% | $2.88 (−7.10%) |
|
Mar 16, 2026
13w ago
|
EFFECT
| $3.10 $2.25 | ▼ −27.42% | ▼ −31.20% | $2.88 (−7.10%) |
|
Mar 2, 2026
14w ago
|
F-1
| $4.75 $2.22 | ▲ +53.26% | ▲ +48.86% | $2.88 (+39.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access